Morgan Stanley Capital Partners

Morgan Stanley Capital Partners is the middle-market private equity arm of Morgan Stanley, investing from a New York base across multiple sectors with a meaningful allocation to defensive healthcare service platforms. Within healthcare the focus sits in Care Delivery and Tech-Enabled Services, and the strategy is a control-oriented buyout approach. AI is not a stated thematic emphasis.

Checks are $25M and above at the growth or buyout stage. The geographic focus is primarily the United States, with the firm leveraging the broader Morgan Stanley platform for sourcing and execution. Named portfolio companies and team members are not specified in the available record; the parent firm’s investor materials and the group’s standalone web presence are the appropriate references.

For AI-native founders, this is not the right address. Morgan Stanley Capital Partners is going to want operating businesses with real cash flow and a defensive profile, not pre-revenue technology bets. Founders running mature healthcare services platforms considering a recapitalization, a strategic exit, or a significant growth investment with a brand-name sponsor should approach with that framing in mind. Expect a structured, institutional diligence process consistent with a bulge-bracket-affiliated investor.